{
  "input": {
    "mode": "execute_actions",
    "query": {
      "entity": "Atypical haemolytic uraemic syndrome",
      "relation": "indication"
    },
    "items": [
      {
        "hypothesis_id": "H1",
        "graph_actions": [
          {
            "type": "stress_test_safety",
            "topic": "风险与副作用",
            "expectation": "评估与非靶向副作用的关联，若存在明显风险，则更新权重",
            "assignee": "Skeptic"
          }
        ]
      },
      {
        "hypothesis_id": "H2",
        "graph_actions": [
          {
            "type": "stress_test_safety",
            "topic": "风险与副作用",
            "expectation": "评估与非靶向副作用的关联，若存在明显风险，则更新权重",
            "assignee": "Skeptic"
          }
        ]
      }
    ],
    "tegraph_snapshot": {
      "nodes": [
        {
          "id": "drug_eculizumab",
          "type": "Drug",
          "label": "Eculizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ravulizumab",
          "type": "Drug",
          "label": "Ravulizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_avacopan",
          "type": "Drug",
          "label": "Avacopan",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_complement_c5_inhibitors",
          "type": "Drug",
          "label": "Complement C5 Inhibitors",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_cangrelor",
          "type": "Drug",
          "label": "Cangrelor",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_nivolumab",
          "type": "Drug",
          "label": "Nivolumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_eculizumab_biosimilar",
          "type": "Drug",
          "label": "Eculizumab Biosimilar",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_tafamidis",
          "type": "Drug",
          "label": "Tafamidis",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ertugliflozin",
          "type": "Drug",
          "label": "Ertugliflozin",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_daratumumab",
          "type": "Drug",
          "label": "Daratumumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_obinutuzumab",
          "type": "Drug",
          "label": "Obinutuzumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_caplacizumab",
          "type": "Drug",
          "label": "Caplacizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "disease_a_hus",
          "type": "Disease",
          "label": "Atypical Haemolytic Uraemic Syndrome",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "target_c5",
          "type": "Target",
          "label": "C5 Complement Protein",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "pathway_complement_system",
          "type": "Pathway",
          "label": "Complement System Pathway",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_ot_eculizumab",
          "type": "Target",
          "label": "OffTarget_Eculizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_eculizumab",
          "type": "Pathway",
          "label": "RiskPathway_Eculizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_eculizumab",
          "type": "Phenotype",
          "label": "AdversePhenotype_Eculizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_ravulizumab",
          "type": "Target",
          "label": "OffTarget_Ravulizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_ravulizumab",
          "type": "Pathway",
          "label": "RiskPathway_Ravulizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_ravulizumab",
          "type": "Phenotype",
          "label": "AdversePhenotype_Ravulizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_avacopan",
          "type": "Target",
          "label": "OffTarget_Avacopan",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_avacopan",
          "type": "Pathway",
          "label": "RiskPathway_Avacopan",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_avacopan",
          "type": "Phenotype",
          "label": "AdversePhenotype_Avacopan",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_c5_inhibitors",
          "type": "Target",
          "label": "OffTarget_C5_Inhibitors",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_c5_inhibitors",
          "type": "Pathway",
          "label": "RiskPathway_C5_Inhibitors",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_c5_inhibitors",
          "type": "Phenotype",
          "label": "AdversePhenotype_C5_Inhibitors",
          "attrs": {
            "agent": "Skeptic"
          }
        }
      ],
      "edges": [
        {
          "source": "drug_eculizumab",
          "target": "target_c5",
          "relation": "inhibits",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "已知机制，多项研究支持其用于aHUS"
        },
        {
          "source": "drug_ravulizumab",
          "target": "target_c5",
          "relation": "inhibits",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "与eculizumab具有相似机制，预期疗效"
        },
        {
          "source": "drug_avacopan",
          "target": "pathway_complement_system",
          "relation": "modulates",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "已知与补体系统交互的机制"
        },
        {
          "source": "drug_complement_c5_inhibitors",
          "target": "pathway_complement_system",
          "relation": "involved_in",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "补体抑制剂归入此类机制"
        },
        {
          "source": "drug_cangrelor",
          "target": "disease_a_hus",
          "relation": "supports",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "潜在关联性，有研究指向抗血小板作用"
        },
        {
          "source": "drug_nivolumab",
          "target": "disease_a_hus",
          "relation": "supports",
          "weight": 0.5,
          "agent": "Proponent",
          "rationale": "需要进一步研究，但部分临床观察相关"
        },
        {
          "source": "drug_eculizumab_biosimilar",
          "target": "target_c5",
          "relation": "inhibits",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "作为原药物的生物仿制药，假设功能相似"
        },
        {
          "source": "drug_tafamidis",
          "target": "disease_a_hus",
          "relation": "supports",
          "weight": 0.4,
          "agent": "Proponent",
          "rationale": "尚需验证但具有潜在机制的药物"
        },
        {
          "source": "drug_ertugliflozin",
          "target": "disease_a_hus",
          "relation": "supports",
          "weight": 0.5,
          "agent": "Proponent",
          "rationale": "近期有初步研究显示效果"
        },
        {
          "source": "drug_daratumumab",
          "target": "disease_a_hus",
          "relation": "supports",
          "weight": 0.4,
          "agent": "Proponent",
          "rationale": "针对特定病理机制，需深入探讨"
        },
        {
          "source": "drug_obinutuzumab",
          "target": "disease_a_hus",
          "relation": "supports",
          "weight": 0.4,
          "agent": "Proponent",
          "rationale": "有针对性，初步数据待确认"
        },
        {
          "source": "drug_caplacizumab",
          "target": "disease_a_hus",
          "relation": "supports",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "已在临床试验中显示疗效"
        },
        {
          "source": "drug_eculizumab",
          "target": "n_ot_eculizumab",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能对非靶点产生副作用"
        },
        {
          "source": "n_ot_eculizumab",
          "target": "n_rp_eculizumab",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "潜在风险通路"
        },
        {
          "source": "n_rp_eculizumab",
          "target": "n_adv_eculizumab",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "导致不良表型"
        },
        {
          "source": "n_adv_eculizumab",
          "target": "H1",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "drug_ravulizumab",
          "target": "n_ot_ravulizumab",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能对非靶点产生副作用"
        },
        {
          "source": "n_ot_ravulizumab",
          "target": "n_rp_ravulizumab",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "潜在风险通路"
        },
        {
          "source": "n_rp_ravulizumab",
          "target": "n_adv_ravulizumab",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "导致不良表型"
        },
        {
          "source": "n_adv_ravulizumab",
          "target": "H2",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "drug_avacopan",
          "target": "n_ot_avacopan",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能对非靶点产生副作用"
        },
        {
          "source": "n_ot_avacopan",
          "target": "n_rp_avacopan",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "潜在风险通路"
        },
        {
          "source": "n_rp_avacopan",
          "target": "n_adv_avacopan",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "导致不良表型"
        },
        {
          "source": "n_adv_avacopan",
          "target": "H3",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "drug_complement_c5_inhibitors",
          "target": "n_ot_c5_inhibitors",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能对非靶点产生副作用"
        },
        {
          "source": "n_ot_c5_inhibitors",
          "target": "n_rp_c5_inhibitors",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "潜在风险通路"
        },
        {
          "source": "n_rp_c5_inhibitors",
          "target": "n_adv_c5_inhibitors",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "导致不良表型"
        },
        {
          "source": "n_adv_c5_inhibitors",
          "target": "H4",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        }
      ],
      "round_index": 4
    },
    "constraints": {
      "max_new_nodes": 50,
      "max_new_edges": 64,
      "batched": true
    },
    "ablation_config": {
      "enable_debate": true,
      "enable_skeptic": true,
      "enable_pi_interrupts": true,
      "enable_textual_feedback": true,
      "enable_heuristic_transfer": true,
      "enable_seed_regen": true,
      "weights": {
        "path_disjointness": 1.0
      },
      "mode": "graph"
    }
  },
  "output": {
    "hypothesis_id": "H1",
    "executed_actions": [
      {
        "action_ref": 0,
        "status": "done",
        "graph_updates": {
          "set_weights": [
            {
              "edge_id": "e_k1",
              "weight": 0.85,
              "rationale": "已评估非靶向作用的副作用风险较高"
            }
          ],
          "conflict_hotspots": [
            {
              "topic": "风险与副作用",
              "pro_nodes": [
                "drug_eculizumab",
                "drug_ravulizumab"
              ],
              "con_nodes": [
                "n_adv_eculizumab",
                "n_adv_ravulizumab"
              ],
              "note": "潜在风险可能抵消预期疗效"
            }
          ]
        },
        "notes": "已完成风险与副作用的评估，更新了权重"
      }
    ],
    "unexecuted_actions": [],
    "residual_conflicts": [
      "药物对非靶标作用的长期影响尚未明确消解"
    ]
  }
}